European Medicines Agency Validates Gilead Sciences, Inc. (GILD)’s Marketing Application For Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet For Genotype 1 Chronic Hepatitis C Infection
3/28/2014 9:18:04 AM
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Marketing Authorisation Application (MAA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection, has been fully validated and is now under assessment by the European Medicines Agency (EMA). The data included in the application, which was submitted on February 27, 2014, support the use of LDV/SOF among adult patients with genotype 1 HCV infection for eight or 12 weeks, depending on prior treatment history and whether they have cirrhosis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by